Albumin for Patients With Acute Large Vessel Occlusive Stroke Undergoing Endovascular Reperfusion Therapy

Summary

The objective of this study is to evaluate the effectiveness and safety of endovascular therapy combined with 25% human albumin in the treatment of acute large vessel occlusive stroke.

Timeline

Start

2024-08-10

Primary completion

2024-12-20

Completion

2025-03-15

Outcome

Met primary endpoint

paper Albumin reduced infarct volume growth from baseline to day 5 compared with placebo PMID 42010254 ↗

paper P = 0.003 PMID 42010254 ↗

Publications

• Liu Y, Dong X, Zhang W, Hou C, Li C, Chu X, Ma Z, Yi T, Wen C, Liu Y, Sun J, Xu J, Li W, Yang L, Zhang X, Li C, Chen W, Li M, Zhou C, Xu Y, Wu D, Ji X, Wu C. Efficacy and safety of albumin combined with endovascular therapy in the treatment of patients with acute ischemic stroke: a randomized clinical trial. Nat Commun. 2026 Apr 20;17(1):5432. doi: 10.1038/s41467-026-72270-6.
• Liu Y, Dong X, Chu X, Ma Z, Yi T, Wen C, Liu Y, Sun J, Xu J, Li W, Yang L, Wang B, Shi L, Li J, Zhang X, Li C, Chen W, Li C, Wu D, Hou C, Zhou C, Li M, Xu Y, Wu C, Ji X. Albumin for patients with acute large-vessel occlusive stroke undergoing endovascular therapy (ARISE): the protocol of a randomized double-blind trial. Front Neurol. 2025 Jul 18;16:1570184. doi: 10.3389/fneur.2025.1570184. eCollection 2025.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Albumin	Protein / enzyme biologic	0.5 g/kg	Intravenous

Indications